Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CEO Claire Mazumdar sold 15,000 shares of the business's stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $23.61, for a total transaction of $354,150.00. Following the transaction, the chief executive officer directly owned 362,152 shares of the company's stock, valued at $8,550,408.72. The trade was a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Claire Mazumdar also recently made the following trade(s):
- On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total transaction of $122,441.16.
- On Thursday, March 19th, Claire Mazumdar sold 6,905 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.78, for a total transaction of $129,675.90.
- On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.95, for a total transaction of $30,244.20.
- On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total transaction of $704,804.22.
- On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.75, for a total value of $71,568.75.
- On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.
- On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total value of $33,469.64.
Bicara Therapeutics Stock Performance
BCAX stock opened at $23.47 on Tuesday. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -9.28 and a beta of -1.23. The business's 50-day moving average is $18.82 and its two-hundred day moving average is $17.64. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $24.25.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.04. Equities analysts predict that Bicara Therapeutics Inc. will post -2.72 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of BCAX. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics in the fourth quarter worth about $45,000. Legal & General Group Plc raised its stake in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares during the period. Larson Financial Group LLC lifted its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after purchasing an additional 3,595 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after purchasing an additional 3,866 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Bicara Therapeutics by 385.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock valued at $97,000 after buying an additional 4,585 shares in the last quarter.
Wall Street Analysts Forecast Growth
BCAX has been the topic of several recent research reports. Citizens Jmp reiterated a "market outperform" rating and issued a $31.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Bank of America assumed coverage on shares of Bicara Therapeutics in a research report on Wednesday, March 25th. They set a "buy" rating and a $35.00 price objective for the company. BTIG Research reaffirmed a "buy" rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Wedbush reiterated an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Finally, The Goldman Sachs Group boosted their price target on Bicara Therapeutics from $14.00 to $16.00 and gave the company a "neutral" rating in a report on Tuesday, March 31st. Eight investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $28.00.
Get Our Latest Analysis on BCAX
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
